How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

18,217 results for

"grant funding" or "obtaining grants" or "getting grants" or "grant awards" or (grants and "how to")

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

17781. Various G-CSF Regimens to Prevent Infection During Chemotherapy

automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number): Layout table for additonal information Responsible Party: Prof. Dr. V. Tjan-Heijnen, Academisch Ziekenhuis Maastricht ClinicalTrials.gov Identifier: Other Study ID Numbers: 2-2-6 STUDY ZonMw ID 80-82310-98-08006 ( Other Grant/Funding Number: Stichting ZonMW ) EudraCT number 2007-005402-53 ( Other Identifier: Centrale Commissie Mensgebonden Onderzoek CCMO ) First Posted: September 27, 2007 Last Update Posted: December 23, 2009

2007 Clinical Trials

17782. Fangshan / Family-based Ischemic Stroke Study In China

Responsible Party: Yonghua Hu, Executive Dean, Peking University ClinicalTrials.gov Identifier: Other Study ID Numbers: NSFC-30671807 SRFDP-20060001111 ( Other Grant/Funding Number: Ministry of Education, China ) 2001BA703B02 ( Other Grant/Funding Number: Ministry of Science and Technology, China ) NSFC-30872173 ( Other Grant/Funding Number: National Natural Science Foundation of China (NSFC) ) NSFC-81102177 ( Other Grant/Funding Number: National Natural Science Foundation of China (NSFC) ) NSFC-81172744 (...) ( Other Grant/Funding Number: National Natural Science Foundation of China (NSFC) ) First Posted: September 26, 2007 Last Update Posted: December 14, 2011 Last Verified: December 2011 Keywords provided by Yonghua Hu, Peking University: Siblings Additional relevant MeSH terms: Layout table for MeSH terms Stroke Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Vascular Diseases Cardiovascular Diseases

2007 Clinical Trials

17783. Mechanism of Fatty Acid-induced Impairment of Glucose-simulated Insulin Secretion

University Health Network, Toronto Investigators Layout table for investigator information Principal Investigator: Gary F. Lewis, MD University Health Network, Toronto General Hospital More Information Go to Layout table for additonal information Responsible Party: Dr. Gary Lewis, University Health Network ClinicalTrials.gov Identifier: Other Study ID Numbers: 07-0274-B Canadian Diabetes Association ( Other Grant/Funding Number: 777508221 ) First Posted: September 21, 2007 Last Update Posted: June 25

2007 Clinical Trials

17784. Quetiapine Augmentation Versus Clomipramine Augmentation of SSRI for Obsessive-Compulsive Disorder Patients

Study ID Numbers: 968/05 2005/55628-08 ( Other Grant/Funding Number: FAPESP ) First Posted: November 28, 2007 Last Update Posted: October 27, 2017 Last Verified: October 2017 Keywords provided by Juliana Belo Diniz, University of Sao Paulo: obsessive compulsive disorder pharmacological treatment quetiapine clomipramine SSRI Additional relevant MeSH terms: Layout table for MeSH terms Disease Compulsive Personality Disorder Obsessive-Compulsive Disorder Pathologic Processes Personality Disorders

2007 Clinical Trials

17785. Transplantation of Umbilical Cord Blood Following Chemotherapy for Blood Cancers

NA_00001903 ( Other Identifier: JHM IRB ) M052663 ( Other Grant/Funding Number: Children's Cancer Foundation ) First Posted: October 4, 2007 Results First Posted: April 3, 2019 Last Update Posted: April 3, 2019 Last Verified: March 2019 Keywords provided by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: Cord blood stem cell transplantation Ex vivo expansion Alternative donor Additional relevant MeSH terms: Layout table for MeSH terms Leukemia Leukemia, Myeloid, Acute Leukemia, Myeloid

2007 Clinical Trials

17786. Early Detection of Ovarian Cancer

Investigator: Karen H. Lu, MD M.D. Anderson Cancer Center More Information Go to Additional Information: Layout table for additonal information Responsible Party: M.D. Anderson Cancer Center ClinicalTrials.gov Identifier: Other Study ID Numbers: ID01-022 RP160145 ( Other Grant/Funding Number: CPRIT ) First Posted: October 4, 2007 Last Update Posted: November 5, 2018 Last Verified: November 2018 Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA

2007 Clinical Trials

17787. Comparison of Two Psychosocial Therapies for Treating Children With Oppositional-Defiant Disorder

identify and regulate emotions and to solve behavior problems together as a family. Parents assigned to the PMT group will be taught how to respond consistently and appropriately to their child's positive and negative behaviors. Participants assigned to the waitlist control condition group will wait 10 weeks before treatment begins. Participants will attend a 1-hour treatment session each week for 10 weeks. In order to determine whether treatment is effective, participants will be asked to complete (...) a variety of questionnaires, talk with their child about solving problems, and complete a structure diagnostic interview prior to the beginning of treatment, following treatment, and at a 1-year follow-up session. Parents will be asked to submit their child's school grades and school attendance records. If granted permission by the parents, the child's teacher will complete a questionnaire regarding the child's behavior in school for the year prior to participating in the study and up to 1 year after

2007 Clinical Trials

17788. Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy

31, 2007 Last Update Posted : March 15, 2019 Sponsor: Case Comprehensive Cancer Center Collaborator: National Cancer Institute (NCI) Information provided by (Responsible Party): Case Comprehensive Cancer Center Study Details Study Description Go to Brief Summary: RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well imatinib mesylate works in treating patients with newly diagnosed (...) Heart Association Criteria. (i.e., congestive heart failure, myocardial infarction within 6 months of study) Patient has known chronic liver disease (i.e., chronic active hepatitis, and cirrhosis). Patient previously received radiotherapy to ≥ 25 % of the bone marrow Patient had a major surgery within 2 weeks prior to study entry. Patient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent. Contacts and Locations Go to Information

2007 Clinical Trials

17789. Effects of Yoga in Breast Cancer Patients

Identifier: Other Study ID Numbers: 2005-0522 CA102385 ( Other Grant/Funding Number: NCI ) NCI-2010-00743 ( Registry Identifier: NCI CTRP ) First Posted: July 30, 2007 Last Update Posted: May 3, 2018 Last Verified: May 2018 Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by M.D. Anderson Cancer Center: Breast Cancer Tibetan Yoga Stretching Program Yoga Quality of Life Questionnaire Survey Additional

2007 Clinical Trials

17790. Development and Validation of a Mindfulness Intervention for Problem Gambling: An Exploratory Study

, gambling cognitions and gambling-related expenditures compared to the relaxation-enhanced CBT (RCBT) at end-of-treatment and at the 3-month follow-up. Significance feasibility of mindfulness interventions for problem gamblers tentative data for the effectiveness of the intervention an additional clinical tool to treat problem gamblers basis of a larger, grant-funded study obtain more definitive data Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial

2007 Clinical Trials

17791. Dexamethasone for Symptom Burden in Advanced Cancer Patients

. Investigators Layout table for investigator information Principal Investigator: Sriram Yennurajalingam, MD M.D. Anderson Cancer Center More Information Go to Additional Information: Layout table for additonal information Responsible Party: M.D. Anderson Cancer Center ClinicalTrials.gov Identifier: Other Study ID Numbers: 2005-0816 NCI-2012-01646 ( Registry Identifier: NCI CTRP ) MRSG-07-001-01-CCE ( Other Grant/Funding Number: American Cancer Society ) First Posted: June 21, 2007 Last Update Posted

2007 Clinical Trials

17792. Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer

in the clinic. You may receive up to 6 cycles of the study treatment. Your continued participation in this study depends on how the cancer responds to the study drugs. Your doctor may decide to take you off this study if you experience intolerable side effects or the medical condition gets worse. After you have completed all of your treatment, you will have an end-of-study visit. At this visit you will have a physical exam, including measurement of your vital signs and weight. You will have a performance (...) or with inability to grant reliable informed consent. Patients must agree not to use herbal remedies or other over-the-counter biologics (i.e. shark cartilage) History of hypersensitivity to docetaxel or other taxane therapy. History of severe hypersensitivity reaction to drugs formulated with polysorbate 80. Patients taking therapeutic levels of warfarin. However, patients receiving 1 mg daily for catheter related anticoagulation are eligible for the study. Prior pericardial effusion requiring intervention

2007 Clinical Trials

17793. Methylene Blue in Sepsis: A Randomized Controlled Trial

provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00486174 Sponsors and Collaborators Queen's University The Physicians' Services Incorporated Foundation Investigators Layout table for investigator information Principal Investigator: Daniel W Howes, MD Queen's University More Information Go to Layout table for additonal information Responsible Party: Dr. Daniel W Howes, Queen's University ClinicalTrials.gov Identifier: Other Study ID Numbers: EMED (...) -090-07 PSI Grant application #2006-36 First Posted: June 14, 2007 Last Update Posted: May 29, 2008 Last Verified: May 2008 Keywords provided by Queen's University: Sepsis Methylene Blue Norepinephrine Additional relevant MeSH terms: Layout table for MeSH terms Sepsis Toxemia Infection Systemic Inflammatory Response Syndrome Inflammation Pathologic Processes Norepinephrine Methylene Blue Adrenergic alpha-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms

2007 Clinical Trials

17794. Belatacept Post Depletional Repopulation to Facilitate Tolerance

automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number): Layout table for additonal information Responsible Party: Antonio Guasch, M.D., Professor, Emory University ClinicalTrials.gov Identifier: Other Study ID Numbers: IRB00005064 Grant # FD-R-003539 ( Other Grant/Funding Number: FDA Office of Orphan Products ) eIRB 00005064 ( Other Identifier: Emory University Institutional Review Board ) BMS IM103-036 ( Other Identifier: Other ) First Posted: November 30, 2007 Last Update Posted

2007 Clinical Trials

17795. Seprafilm® Adhesion Barrier and Cesarean Delivery

to Layout table for additonal information Responsible Party: Daniel Kiefer, Principal Investigator, Winthrop University Hospital ClinicalTrials.gov Identifier: Other Study ID Numbers: IRB No. 07023 MO1RR10710 ( Other Grant/Funding Number: General Clinical Research Center (GCRC) ) First Posted: November 30, 2007 Results First Posted: April 22, 2016 Last Update Posted: April 22, 2016 Last Verified: March 2016 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No Keywords provided

2007 Clinical Trials

17796. Radiation Therapy and Androgen Deprivation Therapy in Treating Patients Who Have Undergone Surgery for Prostate Cancer (RADICALS)

: Other Study ID Numbers: CDR0000571528 MRC-RADICALS-PR10 ISRCTN40814031 EUDRACT-2006-000205-34 EU-20767 PR13 PR13 ( Other Grant/Funding Number: Canadian Cancer Society - Research Institute ) First Posted: October 8, 2007 Last Update Posted: October 13, 2017 Last Verified: October 2017 Keywords provided by Medical Research Council: sexual dysfunction urinary complications gastrointestinal complications adenocarcinoma of the prostate stage I prostate cancer stage IIB prostate cancer stage IIA prostate (...) , or bicalutamide, may lessen the amount of androgens made by the body. Giving radiation therapy together with androgen deprivation therapy may kill more prostate cancer cells. PURPOSE: This randomized phase III trial is studying how well giving radiation therapy together with androgen deprivation therapy works in treating patients who have undergone surgery for prostate cancer. Condition or disease Intervention/treatment Phase Gastrointestinal Complications Prostate Cancer Sexual Dysfunction Urinary

2007 Clinical Trials

17797. Effect of Genistein in Women With Metabolic Syndrome

Principal Investigator: Rosario D'Anna, professor University of Messina, Italy Principal Investigator: Francesco Squadrito, MD University of Messina More Information Go to Publications: Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number): Layout table for additonal information Responsible Party: Rosario D'anna, Associate Professor, University of Messina ClinicalTrials.gov Identifier: Other Study ID Numbers: RODA-12254 20073XZSR3 ( Other Grant/Funding Number

2007 Clinical Trials

17798. Depression Treatment and Screening in Ovarian Cancer Patients

information Principal Investigator: Eileen H. Shinn, PhD M.D. Anderson Cancer Center More Information Go to Additional Information: Layout table for additonal information Responsible Party: M.D. Anderson Cancer Center ClinicalTrials.gov Identifier: Other Study ID Numbers: ID02-258 NCI-2012-02127 ( Registry Identifier: NCI CTRP ) 1CF2002-0000832 HM 01 ( Other Grant/Funding Number: Lance Armstrong Foundation ) First Posted: August 13, 2007 Last Update Posted: January 24, 2018 Last Verified: January 2018

2007 Clinical Trials

17799. Vaccine Therapy in Treating Patients With Stage D0 Prostate Cancer

: Kael-GemVax Co., Ltd. Collaborator: National Cancer Institute (NCI) Information provided by (Responsible Party): Kael-GemVax Co., Ltd. Study Details Study Description Go to Brief Summary: RATIONALE: Vaccines made from tumor cells may help the body build an effective immune response to kill tumor cells. PURPOSE: This randomized phase II trial is studying vaccine therapy to see how well it works compared with a placebo in treating patients with stage D0 prostate cancer. Condition or disease (...) -related immunotherapy Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00514072 Locations Layout table for location information United States, Maryland Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office Bethesda, Maryland

2007 Clinical Trials

17800. Transporter Mediated Uptake of Montelukast

Information Go to Additional Information: Publications: Layout table for additonal information Responsible Party: Ed Mougey, Reserach Scientist, Nemours Children's Clinic ClinicalTrials.gov Identifier: Other Study ID Numbers: 32711 32-03215-003 ( Other Grant/Funding Number: Nemours internal activity number ) First Posted: August 9, 2007 Last Update Posted: January 24, 2014 Last Verified: January 2014 Keywords provided by Ed Mougey, Nemours Children's Clinic: Pharmacogenetics Singulair montelukast (...) that Singulair requires these transporters to be efficiently absorbed. Eventually, what we learn from this work will allow doctors to quickly test individuals with asthma to determine how well they will absorb Singulair and possibly other LTRAs. Knowing this will allow the doctor to adjust the drug treatment on an individual basis to maximize benefit in the treatment of asthma. Condition or disease Intervention/treatment Phase Asthma Dietary Supplement: Grapefruit juice Dietary Supplement: Orange Juice

2007 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>